KWF: open calls

PPP call for projects strengthening Pb-212 production/supply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration and be submitted through KWF GMS; projects are embedded in a national TRT innovation network. Clinical trials and full therapeutic product development are out of scope.

PPP call for projects strengthening Pb-212 production/supply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration with 40–60% industry co-funding, be submitted through KWF GMS, and align with Lead4Life governance and national TRT network. Clinical trials and full therapeutic product development are out of scope.

Add-on funding for ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection) that have reached at least TRL 3. Supports translational pathway definition, targeted development/validation, and regulatory/implementation preparation. TTO commitment letter mandatory; collaboration with TTO of applicant's research institution required.

Supports translation of KWF-funded innovations toward real-world application. Eligible only for ongoing or recently completed KWF projects (up to 1 year after completion). Covers steps such as external expertise, regulatory preparation, or business case development.

Add-on to ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection). Innovation must be at TRL ≥3. Applicants must collaborate with their institution's TTO. Supports translation pathway definition, limited development/validation, and regulatory/implementation preparation. Dutch research institutions only.

Late-phase (phase 2/3) international clinical trials on radiotherapy or surgery for rare cancers (incidence <6/100,000/yr) and/or hard-to-treat cancers (5-yr survival <25%). Consortium must include partners from ≥3 of 5 funding countries (BE, NL, ES, NO, SE). Five projects invited to full proposal phase; submission via Swedish Cancer Society's Grant Application System.

Open to researchers at Dutch institutions with an ongoing or recently finished KWF drug research project (start ≥6 months ago, end ≤1.5 years before 1 July 2026). Funds access to clinically relevant preclinical models, technologies and expertise (NAMs, PDOs, GEMMs, orthotopic models, CRO collaborations) to improve translational value. TRL ≥3 required; activities must relate to drug development/optimisation, not fundamental research alone.

Add-on funding exclusively for ongoing or recently completed KWF projects to strengthen translational relevance of oncology drug development. Supports training, implementation, and validation of advanced preclinical models; outsourcing to academic service providers or CROs is allowed.

Funds academic-led clinical trials (Phase I–III) for new investigational medicinal products in oncology addressing unmet medical needs. Lead institute must be a medical centre or research institute in the Netherlands; public participating parties must be in Europe. Patient involvement is mandatory. Phase I/I-II budget: €1–2.5M; Phase II/III: €1–5M. Proposals must be in English. Public-private partnerships allowed; repurposing of registered drugs is out of scope.

Funds fundamental (Basic) and Credentialing cancer research, including biological mechanisms of cancer onset/progression and psychosocial impacts. Open to Research Project, Consortium, and Unique High-Risk proposal types. Participating institutes must be registered in KWF GMS at least 6 weeks before closing. YIG proposals must be submitted under the separate 2026/YIG call.

Dedicated to basic research uncovering mechanisms driving cancer onset, growth, and spread. Intended for proposals within the Basic research and Credentialing phases. Aims to address knowledge gaps and identify new leads for prevention, diagnosis, and treatment.

Funds fundamental (Basic Research phase 1) and Credentialing (phase 2) cancer research, including biological mechanisms of cancer onset/progression and psychosocial impacts. Proposal types: Research Project, Consortium, and Unique High-Risk. Submitted via KWF GMS; participating institutes must register ≥6 weeks before closing. YIG proposals must use the separate 2026/YIG call.

Health~Holland PPP programme focused on lead-212 (Pb-212) radiopharmaceuticals for cancer treatment. Two pillars: (1) Pb-212 production & supply chain; (2) enabling technologies for clinical introduction. Proposals must include a private party (not in financial difficulty) and comply with Health~Holland PPP requirements. Consortium Agreement required. Submission via KWF GMS; unregistered institutes must register ≥6 weeks before deadline.

Add-on to an ongoing or recently completed KWF-funded project (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection). Innovation must be at TRL ≥3. Applicants must collaborate with their institution's TTO. Supports translational pathway definition, limited development/validation, and regulatory/implementation preparation. Dutch research institutions only (KWF-funded projects).

Supports translation of KWF-funded innovations toward real-world application. Eligible only for ongoing or recently completed KWF projects (up to 1 year after completion). Covers steps such as external expertise, regulatory preparation, or business case development.

Add-on funding for ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection) that have reached at least TRL 3. Supports translational pathway definition, targeted development/validation, and regulatory/implementation preparation. TTO commitment letter mandatory; collaboration with TTO of applicant's research institution required.

PPP proposals for lead-212 production/supply chain or enabling technologies for clinical introduction of Pb-212 radiopharmaceuticals. Requires active private-party participation (Health~Holland PPP rules), a Consortium Agreement, and compliance with RVO 'no undertaking in difficulty' declaration. Dutch-language summary required for patient advisory review. Netherlands-based institutions; unregistered institutes must register in KWF GMS ≥6 weeks before deadline.

Public-private partnership (PPP) call under Health~Holland for development of lead-212 production technology and enabling technologies for clinical radiopharmaceutical application. Proposals must include a private party (not an undertaking in difficulty) and comply with Health~Holland PPP requirements. Dutch Summary required for Patient Advisory Committee review. Participating institutes not yet registered must request access at least 6 weeks before closing.

Health~Holland PPP call for 1–6 projects on enabling technologies for safe clinical use of Pb-212 radiopharmaceuticals (chelators, radiobiology, dosimetry, QC, hospital infrastructure). Requires a public-private consortium with signed Consortium Agreement and Health~Holland PPP compliance. Private party must not be an undertaking in difficulty (RVO declaration required). Clinical/patient-sample context likely.

Health~Holland PPP call for development of lead-212 production/supply chain and enabling technologies for clinical radiopharmaceutical use. Proposals must include a private party (not in financial difficulty) and comply with Health~Holland PPP requirements. Dutch-language summary required for Patient Advisory Committee review. Institutions not yet registered in KWF GMS must apply at least 6 weeks before closing date.

Health~Holland PPP call for radiopharmaceutical research on lead-212 (alpha-emitting isotope) for cancer treatment. Two pillars: (1) Pb-212 production & supply chain; (2) enabling technologies for clinical introduction. Proposals must include a private-party partner not in financial difficulty (RVO declaration required). Dutch Summary reviewed by Patient Advisory Committee. Institutes not yet registered in KWF GMS must apply at least 6 weeks before closing.

Open to multidisciplinary consortia (min. 4 parties) implementing clinically validated oncology biomarkers into nationwide routine care at TRL 7–9. Mandatory components include an HTA specialist in the team, a KWF-approved steering committee, and embedded patient perspective. Public-private collaborations encouraged with co-funding. Proposals submitted via KWF GMS; unregistered institutes must register ≥6 weeks before closing.

Clinical validation of known oncology biomarkers (TRL5/6) for use in daily clinical practice. Requires multidisciplinary consortium of ≥4 parties, mandatory early HTA, patient involvement (PACO review = 30% of score), and biostatistics expertise. AI-component projects must engage the AI4HEALTH consortium. Dutch host institutions implied; public-private collaborations encouraged with co-funding.

Funds fundamental (basic and credentialing) cancer research covering biological mechanisms of cancer onset/progression and psychosocial impacts. Proposals must be submitted via KWF GMS; participating institutes not yet registered must request access at least 6 weeks before closing. This is KWF's final project-based Exploration Call; from 2028 KWF transitions to Research Group Funding.

Translates clinical-grade oncology biomarkers (TRL 7) to nationwide implementation. Open to any tumour type with a clear clinical need. Requires a research consortium of 4+ parties; for-profit partners (>250 FTE) must contribute 10% co-financing. An HTA expert must be part of the project team. Eligibility checklist must be submitted before pre-proposal. PhD positions strongly discouraged due to fail-fast termination risk.

Open to researchers with an ongoing or recently finished KWF project (start ≥6 months ago; end ≤1.5 years before 1 July 2026). Funds additional clinically relevant preclinical drug research activities (advanced models, NAMs, in vivo systems, external CRO validation) not budgeted in the related KWF project. Host institution must be a Dutch knowledge institution registered in KWF GMS. TRL ≥3 required. Drug research scope only; basic research eligible only if directly tied to drug development.

Funds multidisciplinary research and infrastructure to identify, reach, and inform individuals with very high breast cancer risk (BRCA1/2 or PALB2 mutations) and to build a registry for high-risk families. Consortium of ≥4 partners required; patient/citizen participation plan mandatory; early HTA required. In-kind/matching contributions encouraged. Excludes exploratory risk-factor discovery, new screening technologies, and clinical trials.

Funds clinical validation of known cancer biomarkers (TRL5/6) for use in daily clinical practice. Requires a multidisciplinary consortium of ≥4 parties including biostatistician and HTA expert; patient involvement mandatory. For-profit partners >250 FTE must co-finance 10% of KWF budget. Early HTA is a mandatory application component. All cancer types eligible; biomarkers for treatment side-effect prediction are out of scope.

Open to existing oncology infrastructure projects (biobanks, databases, facilities, platforms) seeking a viable business model. At least one partner must be a KWF-funded infrastructure. Funding is not for continuation of original infrastructure plans or personnel salary extensions. Dutch knowledge institutions implied; proposals submitted via KWF-GMS.